AC immune awarded grants supporting TDP-43 detection
AC Immune has been awarded two research grants to identify the presence of TDP-43, a protein that plays a…
Articles by Steve Bryson, PhD
Dosing begins in Phase 1 safety study of new LRRK2 inhibitor
Dosing has begun in a Phase 1 clinical trial of healthy volunteers to evaluate the safety and pharmacological properties of NEU-723,…
Variability in platelet size may be biomarker for Parkinson’s: Study
Researchers have discovered a new genetic link between platelets in the bloodstream and Parkinson’s disease, according to a large-scale…
Nerve Cell Pentraxin Proteins May Be New Biomarkers in Parkinson’s
Levels of nerve cell pentraxin proteins found in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord are associated…
Trial Testing Cough Medicine Ambroxol Starting Soon
The world-first Phase 3 clinical trial testing the ability of ambroxol, a medicine used for decades to treat lung conditions,…
Trial Testing Psilocybin in Parkinson’s Nears End
A clinical trial testing the impact of low doses of psilocybin, a naturally occurring psychedelic compound, on inflammatory activity in…
World’s Largest Parkinson’s Gene Study Expands Into 10 Countries
Centogene is expanding enrollment in the Rockstock International Parkinson’s Disease (ROPAD) gene study — the world’s largest research effort…
Deferiprone Found to Worsen, Not Ease Symptoms in Phase 2 Trial
Deferiprone, an iron chelator (binder) therapy, does not slow the progression of Parkinson’s disease in newly diagnosed patients who…
Blood Biomarkers Identified for Cognitive Changes With Parkinson’s
Blood levels of small vesicles originating in neurons and containing proteins related to Parkinson’s disease or Alzheimer’s disease —…
Blood Biomarker NfL May Predict Cognitive Decline
Levels of neurofilament light chain (NfL) protein in the bloodstream of people with Parkinson’s disease can independently predict cognitive decline,…